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RESEARCH • RECHERCHE
Use of the Corail stem for revision total hip 
arthroplasty: evaluation of clinical outcomes  
and cost
Background: With the growing number of total hip arthroplasty (THA) procedures 
performed, revision surgery is also proportionately increasing, resulting in greater 
health care expenditures. The purpose of this study was to assess clinical outcomes 
and cost when using a collared, fully hydroxyapatite-coated primary femoral stem for 
revision THA compared to commonly used revision femoral stems.
Methods: We retrospectively identified patients who underwent revision THA with 
a primary stem between 2011 and 2016 and matched them on demographic variables 
and reason for revision to a similar cohort who underwent revision THA. We 
extracted operative data and information on in-hospital resource use from the 
patients’ charts to calculate average cost per procedure. Patient-reported outcomes 
were recorded preoperatively and 1 year postoperatively.
Results: We included 20 patients in our analysis, of whom 10 received a primary 
stem and 10, a typical revision stem. There were no significant between-group differ-
ences in mean Western Ontario and McMaster Universities Osteoarthritis Index 
score, Harris Hip Score, 12-Item Short Form Health Survey (SF-12) Mental Com-
posite Scale score or Physical Composite Scale score at 1 year. Operative time was 
significantly shorter and total cost was significantly lower (mean difference –3707.64, 
95% confidence interval –5532.85 to –1882.43) with a primary stem than with other 
revision femoral stems.
Conclusion: We found similar clinical outcomes and significant institutional cost 
savings with a primary femoral stem in revision THA. This suggests a role for a primary 
femoral stem such as a collared, fully hydroxyapatite-coated stem for revision THA.
Contexte : Avec le nombre croissant d’interventions pour prothèse de hanche (PTH) 
effectuées, la chirurgie de révision est aussi proportionnellement en hausse, ce qui 
entraîne des coûts supérieurs pour le système de santé. Le but de cette étude était 
d’évaluer les résultats cliniques et le coût associés à l’emploi d’une prothèse fémorale 
primaire à collerette entièrement recouverte d’hydroxyapatite pour la révision de PTH, 
comparativement à d’autres prothèses d’usage courant utilisées pour les  révisions.
Méthodes : Nous avons identifié rétrospectivement les patients ayant subi une révi-
sion de PTH avec une prothèse primaire entre 2011 et 2016 et nous les avons assortis 
selon les caractéristiques démographiques et le motif de la révision à une cohorte 
simi laire soumise à une révision de PTH. Nous avons extrait les données sur 
l’opération et sur l’utilisation des ressources hospitalières à partir des dossiers des 
patients pour calculer le coût par intervention. Les résultats déclarés par les patients 
ont été notés avant l’intervention et 1 an après.
Résultats : Nous avons inclus 20 patients dans notre analyse, dont 10 ont reçu une 
prothèse primaire et 10, une révision de prothèse typique. On n’a noté aucune dif-
férence significative entre les groupes pour ce qui est du score WOMAC (Western 
Ontario and McMaster Universities Osteoarthritis Index) moyen pour l’arthrose, du 
score de Harris pour la hanche, ou des sous-échelles santé mentale ou santé physique 
à 1 an du questionnaire SF-12 (12-Item Short Form Health Survey). L’intervention a 
duré significativement moins longtemps et le coût a été significativement moindre 
(différence moyenne –3707,64, intervalle de confiance de 95 % –5532,85 à –1882,43) 
avec une prothèse primaire qu’avec les autres prothèses de révision.
Conclusion : Nous avons observé des résultats cliniques similaires et des économies 
significatives pour l’établissement avec la prothèse primaire utilisée pour la révision de 
PTH. Cela donne à penser que la prothèse fémorale primaire, par exemple, à col-
lerette et entièrement recouverte d’hydroxyapatite, aurait un rôle à jouer pour la révi-
sion de PTH.
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A lthough total hip arthroplasty (THA) is considered a widely successful operation, the increasing num-ber of procedures has resulted in a growing num-
ber of revision operations.1,2 The most common causes for 
revision surgery include instability, mechanical loosening 
and infection.1 Revision THA is associated with longer 
hospital stays and substantially higher costs.1 In addition, 
such cases are challenging owing to structural bone loss, 
and various stem options, such as extensively porous, 
cemented, long proximally coated or modular stems are 
often required to obtain fixation.3,4
In revision THA, it is critical to obtain good fixation 
between the implant–bone interface, which is often 
challenging as, in many cases, the femoral canal is 
smooth and sclerotic.5 The use of cementless femoral 
stems in revision THA is gaining popularity owing to 
the poor initial outcomes following use of cemented 
components.6 However, subsidence with proximally 
coated stems and higher revision rates have made sur-
geons turn to fully porous coated stems.4,6,7 The Corail 
femoral component (DePuy Synthes) is a cementless, 
tapered, fully hydroxyapatite-coated titanium stem 
with good clinical outcomes for both hip fracture man-
agement and THA for arthritis.8–12 The tapered design 
has been reported to avoid medullary canal blocking 
and distributes the stress, and the hydroxyapatite pro-
vides maximal osseointegration.11 However, there are 
concerns regarding loose hydroxyapatite particles, 
which may lead to premature wear and osteolysis.12 
Although few studies have evaluated this stem in revi-
sion THA, results have been positive, with good long-
term function.5
In contrast, modular stems are often used in revision 
settings as they can independently address distal fixation 
and bypass bone loss as well as optimize leg length, offset 
and stability proximally.13 However, this added ease with 
modularity is also associated with increased costs and adds 
a potential site of failure compared to monolithic stems.14 
The results with modular stems have been positive in 
terms of patient-reported outcomes as well as complica-
tions and reoperation for mechanical failure.3,13,15,16
The purpose of this study was to assess clinical outcomes 
and cost with the primary collared fully hydroxyapatite-
coated Corail femoral stem for revision THA compared to 
commonly used revision femoral stems. We hypothesized 
that patient-reported outcomes at 1  year are similar to 
those with revision femoral stems. The substantial cost sav-
ings with the Corail stem could potentially justify the use of 
a primary femoral stem in a revision setting where proximal 
bone stock is deemed acceptable intraoperatively.
Methods
We retrospectively identified patients who underwent 
revision THA with a Corail stem between 2011 and 
2016. We compared this cohort with a group of patients 
who underwent revision THA with a revision stem, 
matched for age, body mass index and reason for revision 
based on an inclusive database search. We extracted 
operative data and information on in-hospital resource 
use from the patients’ charts to calculate the average cost 
per procedure. Total procedure-related costs included 
implant cost and length of time in the operating room 
(from time in to time out). We obtained unit costs using 
administrative data from the case-costing department at 
our institution.
Patients prospectively completed several health-
related quality-of-life instruments, including the West-
ern Ontario and McMaster Universities Osteoarthritis 
Index (WOMAC), Harris Hip Score and 12-Item 
Short Form Health Survey (SF-12) Mental and Phys-
ical Composite Scales, at each visit with their surgeon. 
These instruments were also administered preopera-
tively and 1 year postoperatively. We recorded preop-
erative proximal femoral bone loss for the 2 groups and 
classified this using the Paprosky classification.17 Insti-
tutional ethics board approval was obtained for the 
study.
Statistical analysis
We used descriptive statistics to summarize the num-
ber of reoperations, operating room time, implant 
costs and quality of life for the 2  groups. We per-
formed independent sample t tests to compare patient-
reported outcomes between groups, with p < 0.05 set as 
the level of significance. We used nonparametric boot-
strapping to compare differences in mean costs 
between groups. All costs are reported in 2017 Canad-
ian dollars.
Results
We included 20  patients in our analysis, of whom 10 
received a primary collared Corail stem and 10 received a 
revision stem. Demographic characteristics, reason for 
revision and preoperative proximal femoral bone loss were 
similar between the 2 groups (Table 1). There were no sig-
nificant differences in preoperative patient-reported out-
comes (Table 1) (p > 0.05).
At 1  year postoperatively, there were no significant 
differences in mean WOMAC score (p  = 0.8), mean 
Harris Hip Score (p  = 0.8), mean SF-12 Mental Com-
posite Scale score (p  = 0.9) or mean SF-12 Physical 
Composite Scale score between the groups (p  = 0.3) 
(Table 2).
There were no complications with the Corail stem. 
One patient underwent reoperation owing to persistent 
infection. Five complications occurred in the control 
group, 1  case each of pulmonary embolism, deep vein 
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Corail group  
n =10
Control group  
n = 10
Age 70 ± 8.16 71 ± 9.05 0.8
Male:female ratio 70:30 50:50
Body mass index 31 ± 3.5 31 ± 6.05 > 0.99




Infection (4), aseptic loosening (3), 
pseudotumour (2), other (1)
Type of stem Corail Restoration modular (Stryker) (6), AML 
monoblock (DePuy Synthes) (1), 
Reclaim modular (DePuy Synthes) (1), 
S-ROM modular (DePuy Synthes) (1), 






Type I: 7  
Type II: 2  
Type IIIA: 1
Type I: 6  
Type II: 3  
Type IIIA: 1
Harris Hip Score 47.4 ± 16.27 53.3 ± 13.71 0.4




26.6 ± 3.08 32.7 ± 8.48 0.1




51.3 ± 13.89 49.5 ± 13.05 0.8





45.8 ± 19.68 55.6 ± 22.70 0.4
SD = standard deviation.  
*Except where noted otherwise.
Table 2. Patient-reported outcomes at 1 year postoperatively
Outcome
Mean score ± SD
Mean difference (95% CI)Corail group Control group
Harris Hip Score 79.0 ± 13.29 80.8 ± 17.01 1.8 (–17.97 to 21.57)
12-Item Short Form Health 
Survey Physical Composite 
Scale
38.6 ± 10.66 43.1 ± 7.97 4.5 (–5.15 to 14.15)
12-Item Short Form Health 
Survey Mental Composite Scale
57.1 ± 5.92 56.8 ± 4.43 –0.3 (–5.66 to 5.06)
Western Ontario and McMaster 
Universities Osteoarthritis Index
79.2 ± 16.18 81.0 ± 12.76 1.8 (–13.17 to 16.77)
CI = confidence interval; SD = standard deviation.
Table 3. Operating room and implant costs
Variable
Mean ± SD
Mean difference (95% CI)Corail group Control group
Operating room time, 
min
171 ± 25.14 217 ± 45.09 46 (12.1 to 79.9)
Total cost, $* 5691.17 ± 1006.10 10 721.75 ± 3490.62 –3707.64 (–5532.85 to 
–1882.43)
CI = confidence interval; SD = standard deviation.  
*Time in operating room and implant.
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thrombosis, sciatic nerve palsy, dislocation and greater tro-
chanter fracture. There were no reoperations in the con-
trol group.
The mean operative time was significantly shorter in 
the Corail group than in the control group (Table 3). 
Mean total operating room costs were significantly lower 
in the Corail group (mean difference –828.34, 95% confi-
dence interval –1420.67 to –270.56), as were mean implant 
costs (mean difference –2879.301, 95% confidence interval 
–4293.82 to –1464.79).
discussion
In this retrospective study evaluating the clinical outcomes 
and costs for patients undergoing revision THA with a pri-
mary total hip femoral stem (Corail) compared to a 
matched control group of patients undergoing THA with a 
revision femoral stem, we found that patient-reported out-
comes at 1 year postoperatively were not significantly dif-
ferent between the 2 groups. There were no complications 
in the Corail group, compared to 5  complications in the 
control group; complications in the latter group may be 
overrepresented owing to the small sample. Furthermore, 
operating room time and costs and implant costs also sig-
nificantly favoured the Corail primary stem when used for 
revision THA. Taken together, the results suggest that 
there is a role for the use of a primary femoral stem such as 
the Corail in revision THA, especially in patients with 
minimal bone loss.
The Corail femoral stem is a tapered titanium stem 
with a proximal flared design allowing for a 3-dimensional 
metaphyseal fit.11 Stability is achieved through initial press 
fit and secondarily via fixation through the bone–
hydroxyapatite interface.11,12 The extensive hydroxyapatite 
coating increases biological fixation and allows for even 
stress distribution and good long-term survival.5,12 In a 
retrieval study of 165 patients, Coathup and colleagues18 
found significantly more ingrowth and attachment to 
bone with the hydroxyapatite porous coating than with 
plasma spray or grit-blasted stems. Furthermore, the seal 
between the bone and the implant is purportedly strong 
with the Corail primary stem, which slows down wear 
particle migration, limiting osteolysis.12,18 This stem has 
been shown to have good results when used in the primary 
setting, with survivorship of 96.3% at 23 years.12 Reikerås5 
reported that, of 66  consecutive patients who underwent 
revision THA in which the Corail primary stem was used, 
only 1 required revision for mechanical failure. Although 
8 hips that had a proximal fracture intraoperatively requir-
ing wire fixation, long-term results were good up to 
27 years.
In comparison, the matched cohort consisted of typ-
ical revision modular THA stems including the Restora-
tion modular (Stryker), S-ROM (DePuy Synthes), 
Reclaim (DePuy Synthes) and LPS universal fluted 
 modular (DePuy Synthes) in addition to an AML mono-
block stem (DePuy Synthes). These stems enable the 
surgeon to engage the diaphysis to obtain axial and rota-
tional stability distally.3 A distinct advantage of using a 
modular stem is obtaining a secure fit distally indepen-
dent of the proximal body, which allows for optimization 
of limb length, stability and offset.3 This is especially 
important when there is a mismatch between bone loss 
proximally and distally.15 This was shown by Restrepo 
and colleagues,13 who used a Restoration modular stem 
in 118 patients; limb length was restored to within 5 mm 
in 75% of patients and offset to within 2 mm in 65% of 
patients. Dzaja and colleagues3 reported improvement in 
the WOMAC score and Harris Hip Score in 55 patients 
who underwent revision THA in which the Restoration 
modular stem was used, with 2  patients requiring revi-
sion owing to infection and subsidence. Similarly, in 
161  revision THA procedures in which the Restoration 
modular stem was used, Riesgo and colleagues16 found 
an overall reoperation rate of 14.9% and an aseptic 
 loosening rate of 2% with mean follow-up of 6.1 years. 
However, there are risks of junction failure and cor-
rosion in addition to cost concerns when using modular 
femoral stems, especially in patients with minimal bone 
loss.14
Limitations
The limitations of this study include the small sample and 
the short follow-up period. Large prospective studies are 
warranted to support our results. However, the goal of 
this study was to compare early failures with a primary 
total hip femoral stem used in a revision setting and the 
cost differences as compared to revision femoral stems. 
Although it is recognized that a primary femoral compo-
nent should be used only in specific circumstances, we 
mitigated this limitation by matching to revision cases 
with similar indications for revision surgery. In patients in 
whom the calcar is intact and there is minimal bone loss, 
with overall robust proximal femoral bone quality, a pri-
mary femoral stem can be appropriately used for revision 
THA.
conclusion
Our results suggest a role for a primary femoral stem such 
as the Corail for revision THA. We found similar clinical 
outcomes and substantial institutional cost savings com-
pared to a matched control group who received revision 
femoral stems. Therefore, taking into account patient 
 factors including bone deficiency, a collared, fully 
hydroxyapatite-coated stem such as the Corail primary 
femoral stem can play a role in revision THA, with com-
parable early clinical results to those with other revision 
femoral stems.
RECHERCHE
82 J can chir, Vol. 62, No 2, avril 2019 
Affiliations: From the Division of Orthopaedic Surgery, Department of 
Surgery, London Health Sciences Centre, University Campus, Western 
University, London, Ont. (Wood, Alzahrani, Vasarhelyi, Lanting); the 
Department of Orthopaedic Surgery, Imam Abdulrahman Bin Faisal 
University, Dammam, Saudi Arabia (Alzahrani); the School of Physical 
Therapy, Faculty of Health Sciences, Western University, London, 
Ont. (Marsh); and the Bone and Joint Institute, Western University, 
London, Ont. (Marsh, Vasarhelyi, Lanting).
Competing interests: E. Vasarhelyi and B. Lanting have received con-
sulting fees and research support from Smith & Nephew, DePuy 
Synthes and Stryker. No other competing interests declared.
Contributors: T. Wood, L. Somerville, E. Vasarhelyi and B. Lanting 
designed the study. T. Wood, J. Marsh, L. Somerville and E. Vasarhelyi 
acquired the data, which all authors analyzed. T. Wood, M. Alzahrani 
and L. Somerville wrote the article, which all authors reviewed and 
approved for publication.
References
 1. Bozic KJ, Kurtz SM, Lau E, et al. The epidemiology of revision total 
hip arthroplasty in the United States. J Bone Joint Surg Am 2009;91: 
128-33.
 2. Kurtz S, Ong K, Lau E, et al. Projections of primary and revision hip 
and knee arthroplasty in the United States from 2005 to 2030. J Bone 
Joint Surg Am 2007;89:780-5.
 3. Dzaja I, Lyons MC, McCalden RW, et al. Revision hip arthroplasty 
using a modular revision hip system in cases of severe bone loss. J 
Arthroplasty 2014;29:1594-7.
 4. Malkani AL, Lewallen DG, Cabanela ME, et al. Femoral component 
revision using an uncemented, proximally coated, long-stem prosthe-
sis. J Arthroplasty 1996;11:411-8.
 5. Reikerås O. Femoral revision surgery using a fully hydroxyapatite-
coated stem: a cohort study of twenty two to twenty seven years. Int 
Orthop 2017;41:271-5.
 6. Barrack RL, Folgueras AJ. Revision total hip arthroplasty: the femo-
ral component. J Am Acad Orthop Surg 1995;3:79-85.
 7. Mulliken BD, Rorabeck CH, Bourne RB. Uncemented revision total 
hip arthroplasty: a 4-to-6-year review. Clin Orthop Relat Res 1996; 
325:156-62.
 8. Cawley DT, Curtin PD, Lohan D, et al. The Corail® stem for the 
treatment of displaced femoral neck fractures — a viable alternative. 
Hip Int 2011;21:243-50.
 9. Drobniewski M, Borowski A, Synder M, et al. Results of total 
cementless hip joint arthroplasty with Corail stem. Ortop Traumatol 
Rehabil 2013;15:61-8.
10. Hallan G, Lie SA, Furnes O, et al. Medium- and long-term perfor-
mance of 11,516 uncemented primary femoral stems from the Nor-
wegian Arthroplasty Register. J Bone Joint Surg Br 2007;89:1574-
80.
11. Xu J, Xie Z, Zhao J, et al. Results of a hydroxyapatite-coated femoral 
stem (Corail) in Chinese: a minimum 10-year follow up. Springerplus 
2016;5:1983.
12. Vidalain JP. Twenty-year results of the cementless Corail stem. Int 
Orthop 2011;35:189-94.
13. Restrepo C, Mashadi M, Parvizi J, et al. Modular femoral stems for 
revision total hip arthroplasty. Clin Orthop Relat Res 2011;469:476-82.
14. Sivananthan S, Lim CT, Narkbunnam R, et al. Revision hip arthro-
plasty using a modular, cementless femoral stem: intermediate-term 
follow-up. J Arthroplasty 2017;32:1245-9.
15. Stimac JD, Boles J, Parkes N, et al. Revision total hip arthroplasty 
with modular femoral stems. J Arthroplasty 2014;29:2167-70.
16. Riesgo AM, Hochfelder JP, Adler EM, et al. Survivorship and com-
plications of revision total hip arthroplasty with a mid-modular fem-
oral stem. J Arthroplasty 2015;30:2260-3.
17. Sheth NP, Nelson CL, Paprosky WG. Femoral bone loss in revision 
total hip arthroplasty: evaluation and management. J Am Acad Orthop 
Surg 2013;21:601-12.
18. Coathup MJ, Blunn GW, Flynn N, et al. A comparison of bone 
remodeling around hydroxyapatite-coated, porous-coated and grit-
blasted hip replacements retrieved at post-mortem. J Bone Joint Surg 
Br 2001;83:118-23.
We believe in open access  
to research
To ensure continued worldwide free access to all CJS content, 
articles submitted for publication are subject to a submission 
fee of $100 (Canadian funds). Submission fees are waived for 
cor responding authors affiliated with CJS sponsors. Accepted 
Research and Review articles are subject to a publication fee of $800, and Commentaries and Discussions are 
subject to a publication fee of $600, payable on acceptance in Can adian funds. Corresponding authors affiliated 
with CJS sponsors receive a $100 discount on publication fees.
 Benefits of open access
• For researchers and institutions: increased visibility, usage and impact for their work
• For government: a better return on investment for funding research
• For society: efficient, effective patient care resulting in better outcomes
CJS articles are available free of charge on the journal website (canjsurg.ca) and in PubMed Central.
